Teva Pharmaceutical Industries Ltd. aims to close its $40.5 billion acquisition of Allergan Plc’s generic business by the end of the month. Undaunted by falling prices for generics, the Israeli drugmaker is ramping up production. It plans to launch 1,000 new products this year -- more than double the 2015 tally -- and 1,500 the next.
Before it's here, it's on the Bloomberg Terminal. LEARN MORE